摘要:The coronavirus disease 2019(COVID-19)pandemic has had a tremendous adverse impact on the global health system,public sector,and social aspects.It is unarguably the worst pandemic of the century.However,COVID-19 management is a mystery in front of us,and an authentic treatment is urgently needed.Various repurposed drugs,like ivermectin,remdesivir,tocilizumab,baricitinib,etc.,have been used to treat COVID-19,but none are promising.Antibody therapy and their combinations are emerging modalities for treating moderate COVID-19,and they have shown the potential to reduce hospitalisations.One antibody monotherapy,bamlanivimab,and two cocktails,casirivimab/imdevimab and bamlanivimab/esterivimab,have received authorization for emergency use by the United States Food and Drug Administration for the treatment of mild COVID-19 in high risk individuals.The European Emergency has made similar recommendations for use of the drug in COVID-19 patients without oxygen therapy.This brief review will focus on monoclonal antibodies and their combination cocktail therapy in managing COVID-19 infection.